Published in Cancer Weekly, April 8th, 2003
According to recent research from Singapore, "hepatitis B surface antigen (HBsAg) positive hepatocellular carcinoma (HCC) patients have a high risk of recurrence within 5 years of hepatic resection and suitable long-term maintenance therapy is required."
"An open-ended controlled trial on 30 HBsAg positive Child Pugh's grade A cirrhotic patients was started in September 1986 using Wellferon (natural lymphoblastoid alpha interferon). Ten patients had standard adriamycin and mitomycin C monthly for 6 months, then discontinued when the course was...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Cancer Weekly
Source: Cancer Weekly (2003-04-08)
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.